Cargando…

Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study

Objective To determine the association between concentration of prostate specific antigen (PSA) at age 40-55 and subsequent risk of prostate cancer metastasis and mortality in an unscreened population to evaluate when to start screening for prostate cancer and whether rescreening could be risk strat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vickers, Andrew J, Ulmert, David, Sjoberg, Daniel D, Bennette, Caroline J, Björk, Thomas, Gerdtsson, Axel, Manjer, Jonas, Nilsson, Peter M, Dahlin, Anders, Bjartell, Anders, Scardino, Peter T, Lilja, Hans
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933251/ https://www.ncbi.nlm.nih.gov/pubmed/23596126 http://dx.doi.org/10.1136/bmj.f2023

Ejemplares similares

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study
por: Vickers, Andrew J, et al.
Publicado: (2010)

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
por: Vickers, Andrew J, et al.
Publicado: (2014)

Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study
por: Carlsson, Sigrid, et al.
Publicado: (2014)

Long-term prediction of prostate cancer diagnosis and death using PSA and obesity related anthropometrics at early middle age: data from the malmö preventive project
por: Assel, Melissa J., et al.
Publicado: (2017)

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study
por: Ulmert, David, et al.
Publicado: (2008)

Prostate cancer polygenic risk score and prediction of lethal prostate cancer
por: Klein, Robert J., et al.
Publicado: (2022)

Increasing rates of urinary and bloodstream infections following transrectal prostate biopsy in South Sweden
por: Ljungquist, Oskar, et al.
Publicado: (2022)

Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6
por: Timmermand, Oskar Vilhelmsson, et al.
Publicado: (2014)

High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression
por: Jonsson, Liv, et al.
Publicado: (2011)

Addition of Prostate Volume and Prostate-specific Antigen Density to Memorial Sloan Kettering Cancer Center Prostate Cancer Nomograms
por: Tzeng, Michael, et al.
Publicado: (2021)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
por: Vickers, Andrew J, et al.
Publicado: (2008)

Elevated Level of Wnt5a Protein in Localized Prostate Cancer Tissue Is Associated with Better Outcome
por: Syed Khaja, Azharuddin Sajid, et al.
Publicado: (2011)

Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study
por: Bryant, Richard J., et al.
Publicado: (2015)

Prostate Cancer Mortality in Areas With High and Low Prostate Cancer Incidence
por: Stattin, Pär, et al.
Publicado: (2014)

A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands
por: Gupta, A, et al.
Publicado: (2010)

Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
por: Kovac, Evan, et al.
Publicado: (2020)

Multiple Cellular Mechanisms Related to Cyclin A1 in Prostate Cancer Invasion and Metastasis
por: Wegiel, Barbara, et al.
Publicado: (2008)

Automatic registration of multi-modal microscopy images for integrative analysis of prostate tissue sections
por: Lippolis, Giuseppe, et al.
Publicado: (2013)

Large Extracellular Vesicle Characterization and Association with Circulating Tumor Cells in Metastatic Castrate Resistant Prostate Cancer
por: Gerdtsson, Anna S., et al.
Publicado: (2021)

Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study
por: Thomsen, Frederik B., et al.
Publicado: (2020)

Feasibility study of a clinically-integrated randomized trial of modifications to radical prostatectomy
por: Vickers, Andrew J, et al.
Publicado: (2012)

Degree of Preservation of Neurovascular Bundles in Radical Prostatectomy and Recurrence of Prostate Cancer
por: Axén, Elin, et al.
Publicado: (2021)

REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer
por: Svensson, Charlotte, et al.
Publicado: (2014)

Galiellalactone Inhibits Stem Cell-Like ALDH-Positive Prostate Cancer Cells
por: Hellsten, Rebecka, et al.
Publicado: (2011)

Cystatin C Is Downregulated in Prostate Cancer and Modulates Invasion of Prostate Cancer Cells via MAPK/Erk and Androgen Receptor Pathways
por: Wegiel, Barbara, et al.
Publicado: (2009)

Prostate specific antigen for early detection of prostate cancer: longitudinal study
por: Holmström, Benny, et al.
Publicado: (2009)

The STAT3 inhibitor GPB730 enhances the sensitivity to enzalutamide in prostate cancer cells
por: Hellsten, Rebecka, et al.
Publicado: (2022)

Global expression of AMACR transcripts predicts risk for prostate cancer – a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate
por: Alinezhad, Saeid, et al.
Publicado: (2016)

Plasma enterolactone and risk of prostate cancer in middle-aged Swedish men
por: Wallström, Peter, et al.
Publicado: (2017)

Prostate Cancer, Prostate Cancer Death, and Death from Other Causes, Among Men with Metabolic Aberrations
por: Häggström, Christel, et al.
Publicado: (2014)

Upregulation of miR-96 Enhances Cellular Proliferation of Prostate Cancer Cells through FOXO1
por: Haflidadóttir, Benedikta S., et al.
Publicado: (2013)

Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer
por: McDevitt, Michael R., et al.
Publicado: (2018)

Contemporary approaches for imaging skeletal metastasis
por: Ulmert, David, et al.
Publicado: (2015)

The percentage of high‐grade prostatic adenocarcinoma in prostate biopsies significantly improves on Grade Groups in the prediction of prostate cancer death
por: Berney, Daniel M, et al.
Publicado: (2019)

Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less
por: LIU, Xin, et al.
Publicado: (2015)

Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome
por: Hammarsten, Peter, et al.
Publicado: (2019)

Emphasizing the role of Wnt5a protein expression to predict favorable outcome after radical prostatectomy in patients with low-grade prostate cancer
por: Khaja, Azharuddin Sajid Syed, et al.
Publicado: (2012)

The STAT3 inhibitor galiellalactone inhibits the generation of MDSC‐like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors
por: Hellsten, Rebecka, et al.
Publicado: (2019)

Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA.
por: Nilsson, O., et al.
Publicado: (1997)

Successful external validation of a model to predict other cause mortality in localized prostate cancer
por: Kent, Matthew, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hhf4cot2eceke406784qce7v6q